

Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual

KCR 2018 SPRING TRAINING

2018 Hematopoietic Database Updates

Updates were done to the Hematopoietic Database based on the WHO Hematopoietic and Lymphoid Neoplasms, Revised 4th edition, Volume II, published in 2017. Changes include:

- Revised preferred terminology for ICD-O-3 codes
- Default primary sites updated (9724, 9727, 9811-9818, 9827, 9837)
- Module information updated - **Module 4 is for lymphoma/leukemia histologies; it is effective for cases diagnosed 2010-2017 only.** For cases diagnosed 1/1/2018 forward, see the Hematopoietic database.

Note: Due to changes between 2010-2017 and 2018, it is very important to choose the diagnosis year when looking for information on a histology.

Primary site for cases diagnosed 01/01/2018 and forward

Assign primary **site C421 (Bone marrow)** when the histology is:

- 9724/3-Systemic EBV-positive T-cell lymphoma of childhood
- 9727/3-Blastic plasmacytoid dendritic cell neoplasm

- 9811/3-B-lymphoblastic leukemia/lymphoma, not otherwise specified (NOS)
- 9812/3-B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
- 9813/3-B-lymphoblastic leukemia/lymphoma with t(v;11q23.3); KMT2A-rearranged
- 9814/3-B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1
- 9815/3-B-lymphoblastic leukemia/lymphoma with hyperdiploidy
- 9816/3-B-lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL)
- 9817/3-B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3-
- 9818/3-B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1
- 9837/3-T lymphoblastic leukemia/lymphoma

Primary site for cases diagnosed 01/01/2018 and forward

Assign primary **site according to lymphoma rules** when the histology is:

- 9827/3-Adult T-cell leukemia/lymphoma

- In 2018 and forward, this will be considered a lymphoma. The primary site will be coded according to the rules in Modules 6 or 7, and not Module 4.

2018 Hematopoietic Database Updates

Other changes in the 2018 Hematopoietic Database:

- Updates to Immunophenotyping, Genetics information
- Update of transformations
- **Grade field changed to “not applicable.”**

New histology codes, (not approved for use in United States and Canada for 2018) will be coming in 2019.

Behavior code changes not yet approved for 2018 (coming in 2019)

Change	New code	Term	Current code	Current Term
Behavior	9709/1	Primary cutaneous CD4+ sm/medium T cell lymphoproliferative disorder	9709/3	Primary cutaneous T cell lymphoma
Behavior	9725/1	Hydroa vacciniforme-like lymphoproliferative disorder	9725/3	Hydroa vacciniforme-like lymphoma
Behavior	9751/1	Langerhans cell histiocytosis	9751/3	Langerhans cell histiocytosis
Behavior	9971/1	Polymorphic post-transplant lymphoproliferative disorder	9971/3	Polymorphic post-transplant lymphoproliferative disorder

New histology codes not yet approved for 2018 (coming in 2019)

Change	Code	Term	Current	Term
New	9715/3	Anaplastic large cell lymphoma, ALK neg	9702/3	Peripheral T cell lymphoma
New	9749/3	Erdheim-Chester disease	N/A	N/A
New	9766/3	Lymphomatoid granulomatosis, grade 3	9680/3	Diffuse large B cell lymphoma
New	9877/3	AML with gene mutations	9861/3	AML, NOS
New	9878/3	AML with biallelic mutation of CEBPA	9861/3	AML, NOS
New	9879/3	AML with mutated RUNX1	9861/3	AML, NOS
New	9912/3	AML with BCR-ABL1	9861/3	AML, NOS
New	9968/3	Myeloid/lymphoid neoplasms w/PCM2-JAK2	9975/3	MDS/Myeloproliferative neoplasm, unclassifiable
New	9980/3	MDS with single lineage dysplasia	9991/3	Refractory neutropenia
New	9980/3	MDS with single lineage dysplasia	9992/3	Refractory thrombocytopenia
New	9993/3	MDS with ring sideroblasts	9985/3	MDS with multilineage dysplasia

Number of primaries

The most important thing to remember from these rules is:

- These rules are for cancer registrars and are not followed by physicians. Follow the rules stated in this manual and abstract the number of primaries based on the rules. This may, or may not, agree with what the physician determines.

Multiple Primaries Calculator

- The multiple primaries calculator (MPC) is to be used ONLY when the rules instruct you to do so. Use of the MPC without applying the rules first may result in a wrong number of primaries and/or the wrong histologies.

Two important changes to the MP rules


Abstract as **2 primaries** when a **nodal MALT lymphoma** occurs before or after an **extranodal MALT lymphoma**. These are 2 distinct lymphomas, with nodal lymphomas coded to lymph nodes (C77.0-C77.9) and extranodal coded to any other site.

Solitary Plasmacytomas (9731/3, 9734/3) occurring after a diagnosis of plasma cell myeloma (or multiple myeloma -9732/3) are NOT new primaries. The presence of plasmacytomas after multiple myeloma is evidence of advanced disease.

Diagnostic confirmation

Diagnostic Confirmation Coding Instructions for Hematopoietic and Lymphoid Neoplasms (9590/3-9992/3)

- Code 1: Positive histology **(includes positive cytology)**
- Code 2 is rarely used for Hematopoietic and Lymphoid neoplasms



Steps for using the hematopoietic database and coding manual

1. Identify the working (**preliminary**) **histology** code(s)
2. Determine the number of primaries using the working histology code(s) with the **MP rules in the manual**
 - Note 1: The M rule references in the Heme DB are to be used as a guide only. Start with rule M1, move through the rules in consecutive order and stop at the first rule that applies.
 - Note 2: Use the Hematopoietic Multiple Primaries Calculator in the Heme DB only when instructed by the rules in the Hematopoietic Manual.
3. Verify or **revise the working histology** code(s) using the PH rules in the manual
4. Determine **primary site**
5. Determine the **grade** (**use only for cases diagnosed 2010-2017. Grade no longer collected for cases diagnosed 2018 and forward**).

Changes to Other therapy

Collect blood-thinners and/or anti-clotting agents for essential thrombocythemia (9962/3) ONLY

Previously, instructions stated that blood thinners and/or anti-clotting agents were also collected for the histologies listed below. **This change is effective for cases diagnosed 1/1/2010 and forward; however, there is no requirement of changing cases already abstracted**

- 9740/3 Mast cell sarcoma
- 9741/3 Systemic mastocytosis with an associated hematological neoplasm
- 9742/3 Mast cell leukemia
- 9875/3 Chronic myeloid leukemia *BCR-ABL1*-positive
- 9950/3 Polycythemia vera
- 9961/3 Primary myelofibrosis
- 9963/3 Chronic neutrophilic leukemia
- 9975/3 Myelodysplastic/myeloproliferative neoplasm, unclassifiable

Immunotherapy

Donor Leukocyte Infusions – Always abstract as immunotherapy even if not listed in treatment section of the Hematopoietic Database

The End

Thank you!

For questions, contact

Frances Ross

fer@kcr.uky.edu